JP2021534220A5 - - Google Patents

Info

Publication number
JP2021534220A5
JP2021534220A5 JP2021510094A JP2021510094A JP2021534220A5 JP 2021534220 A5 JP2021534220 A5 JP 2021534220A5 JP 2021510094 A JP2021510094 A JP 2021510094A JP 2021510094 A JP2021510094 A JP 2021510094A JP 2021534220 A5 JP2021534220 A5 JP 2021534220A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
variable region
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534220A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047728 external-priority patent/WO2020041604A1/en
Publication of JP2021534220A publication Critical patent/JP2021534220A/ja
Publication of JP2021534220A5 publication Critical patent/JP2021534220A5/ja
Priority to JP2024119250A priority Critical patent/JP7818042B2/ja
Priority to JP2026018549A priority patent/JP2026086616A/ja
Pending legal-status Critical Current

Links

JP2021510094A 2018-08-22 2019-08-22 抗her2ポリペプチド及びそれらの使用の方法 Pending JP2021534220A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024119250A JP7818042B2 (ja) 2018-08-22 2024-07-25 抗her2ポリペプチド及びそれらの使用の方法
JP2026018549A JP2026086616A (ja) 2018-08-22 2026-02-06 抗her2ポリペプチド及びそれらの使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721505P 2018-08-22 2018-08-22
US62/721,505 2018-08-22
PCT/US2019/047728 WO2020041604A1 (en) 2018-08-22 2019-08-22 Anti-her2 polypeptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024119250A Division JP7818042B2 (ja) 2018-08-22 2024-07-25 抗her2ポリペプチド及びそれらの使用の方法

Publications (2)

Publication Number Publication Date
JP2021534220A JP2021534220A (ja) 2021-12-09
JP2021534220A5 true JP2021534220A5 (cg-RX-API-DMAC7.html) 2022-08-23

Family

ID=67989062

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021510094A Pending JP2021534220A (ja) 2018-08-22 2019-08-22 抗her2ポリペプチド及びそれらの使用の方法
JP2024119250A Active JP7818042B2 (ja) 2018-08-22 2024-07-25 抗her2ポリペプチド及びそれらの使用の方法
JP2026018549A Pending JP2026086616A (ja) 2018-08-22 2026-02-06 抗her2ポリペプチド及びそれらの使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024119250A Active JP7818042B2 (ja) 2018-08-22 2024-07-25 抗her2ポリペプチド及びそれらの使用の方法
JP2026018549A Pending JP2026086616A (ja) 2018-08-22 2026-02-06 抗her2ポリペプチド及びそれらの使用の方法

Country Status (15)

Country Link
US (1) US20220002436A1 (cg-RX-API-DMAC7.html)
EP (1) EP3840781A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021534220A (cg-RX-API-DMAC7.html)
KR (1) KR20210074279A (cg-RX-API-DMAC7.html)
CN (1) CN113286610A (cg-RX-API-DMAC7.html)
AR (1) AR115998A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019326545A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021002953A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141815A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190603A1 (cg-RX-API-DMAC7.html)
IL (2) IL326298A (cg-RX-API-DMAC7.html)
MX (1) MX2021001976A (cg-RX-API-DMAC7.html)
SG (1) SG11202101436SA (cg-RX-API-DMAC7.html)
TW (1) TW202017947A (cg-RX-API-DMAC7.html)
WO (1) WO2020041604A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CA3170338A1 (en) * 2020-02-19 2021-08-26 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
US20240392035A1 (en) * 2021-08-25 2024-11-28 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
US20250066449A1 (en) * 2021-12-31 2025-02-27 Imnewrun, Inc. Blood-brain barrier permeable fusion protein and uses thereof
KR20240067001A (ko) * 2022-10-28 2024-05-16 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
JP2025540336A (ja) * 2022-12-08 2025-12-11 アデル,インク 抗タウ抗体及びペプチドを含む融合体とその用途
CN120648654A (zh) * 2024-03-13 2025-09-16 深圳太力生物技术有限责任公司 重组细胞的制备方法、重组细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423140T1 (de) * 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
MX367126B (es) * 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
WO2015191934A2 (en) * 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
JP7021955B2 (ja) * 2015-06-24 2022-03-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Her2及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
RS63818B1 (sr) * 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
CA3053379A1 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
WO2019032955A1 (en) * 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES

Similar Documents

Publication Publication Date Title
JP2024150674A5 (cg-RX-API-DMAC7.html)
JP7793679B2 (ja) ヒトTim-3に対するモノクローナル抗体
JP2021533779A5 (cg-RX-API-DMAC7.html)
CN106414494B (zh) 具有促凋亡活性的人IgG1衍生的抗体
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
RU2015145719A (ru) Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
JP2022524588A5 (cg-RX-API-DMAC7.html)
JP2021534220A (ja) 抗her2ポリペプチド及びそれらの使用の方法
AU2018387829B2 (en) Bispecific antigen binding construct
JP2022521305A (ja) 抗pd-l1抗体及びその使用
TW201934578A (zh) 治療方法
JP2026513915A (ja) ヒンジが修飾された二重特異性抗体
US20260109781A1 (en) Anti-her2 antibodies and methods of use thereof
JP2025527160A (ja) 多重特異性抗体およびその使用
AU2022317124B2 (en) Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications
JP2022514615A (ja) ヒト免疫チェックポイントCEACAM1(CD66a)に対するアンタゴニスト抗体及びその製剤、キット並びに使用方法
US20250376536A1 (en) Multispecific anti-cd40 / anti-fap antibodies and uses thereof
JP2025516631A5 (cg-RX-API-DMAC7.html)
RU2777336C1 (ru) Моноклональные антитела к tim-3 человека
US20220153869A1 (en) Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof
HK40123160A (en) Pharmaceutical use of anti-pd-1-anti-vegfa bispecific antibody
JP2021510162A5 (cg-RX-API-DMAC7.html)
TW202519261A (zh) 用於治療癌症之結合γ-δ T細胞受體之抗體
RU2022103028A (ru) Антитела против рецептора программируемой смерти pd-1 человека
HK40043135B (en) Monoclonal antibodies against human tim-3